Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
Okin PM, Wright JT, Nieminen MS, Jern S, Taylor AL, Phillips R, Papademetriou V, Clark LT, Ofili EO, Randall OS, Oikarinen L, Viitasalo M, Toivonen L, Julius S, Dahlöf B, Devereux RB. Okin PM, et al. Among authors: oikarinen l. Am J Hypertens. 2002 Aug;15(8):663-71. doi: 10.1016/s0895-7061(02)02945-x. Am J Hypertens. 2002. PMID: 12160187
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Oikarinen L, Nieminen MS, Toivonen L, Viitasalo M, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM; LIFE Study Investigators. Oikarinen L, et al. Am Heart J. 2003 May;145(5):919-25. doi: 10.1016/S0002-8703(02)94785-X. Am Heart J. 2003. PMID: 12766755 Clinical Trial.
QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Jern S, Dahlöf B, Devereux RB, Okin PM; LIFE Study Investigators. Oikarinen L, et al. Hypertension. 2004 May;43(5):1029-34. doi: 10.1161/01.HYP.0000125230.46080.c6. Epub 2004 Mar 22. Hypertension. 2004. PMID: 15037560 Clinical Trial.
Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Dahlöf B; LIFE Study Investigators. Okin PM, et al. Among authors: oikarinen l. Circulation. 2006 Jan 3;113(1):67-73. doi: 10.1161/CIRCULATIONAHA.105.569491. Epub 2005 Dec 19. Circulation. 2006. PMID: 16365195
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
Okin PM, Wachtell K, Devereux RB, Nieminen MS, Oikarinen L, Viitasalo M, Toivonen L, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Kjeldsen SE, Julius S, Dahlöf B; LIFE Study Investigators. Okin PM, et al. Among authors: oikarinen l. Am J Hypertens. 2008 Mar;21(3):273-9. doi: 10.1038/ajh.2007.66. Epub 2008 Jan 24. Am J Hypertens. 2008. PMID: 18219298 Clinical Trial.
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB; LIFE Study Investigators. Okin PM, et al. Among authors: oikarinen l. Circulation. 2009 Apr 14;119(14):1883-91. doi: 10.1161/CIRCULATIONAHA.108.812313. Epub 2009 Mar 30. Circulation. 2009. PMID: 19332468 Clinical Trial.
73 results